Reduce inflammatory mediators
Decreases the level of pro-inflammatory mediators to inhibit inflammation.
Liu et al. 2017; Yin et al. 2018In-Office Procedures · Intense Pulsed Light
OptiLight by Lumenis A bright solution for dry eye.
The first and only IPL FDA approved for the management of dry eye disease due to meibomian gland dysfunction (MGD). A light-based, 15-minute in-office procedure built on Lumenis' patented Optimal Pulse Technology (OPT™).
~15 minper procedure
4treatment sessions
590–1200 nmwavelength range
35 J/cm²maximal fluence
How it works
Stop the dry eye vicious cycle of inflammation.
An effective multifactorial treatment for a multifactorial disease. OptiLight addresses five contributors to dry eye due to MGD.
Improve tear breakup time
Significantly boosts tear breakup time and decreases osmolarity.
Dell et al. 2017; Toyos & Briscoe 2016Alleviate abnormal blood vessels
Destroys the abnormal blood vessels that perpetuate inflammation.
Kassir et al. 2011; Papageorgiou et al. 2008Restore meibomian glands
Improves meibomian gland morphology and functionality.
Yin et al. 2018Decrease Demodex
Decreases the population of Demodex mites, which stimulate infection and boost the bacterial load on the eyelids.
Prieto et al. 2002Every element designed for a precise, comfortable procedure.
Patented handpieces and Optimal Pulse Technology give the practitioner targeted, uniform, precise and controlled treatment, including on the delicate area beneath the eyes.
- Personalized treatment experience
- Proven treatment protocols
- Designed for the delicate sub-eye area
-
Optimal Pulse Technology (OPT™)
Delivers optimal energy with no-spike consistency, for targeted, uniform, precise and controlled treatment.
-
Patented OPT™ handpiece
Customizes treatment to each patient's facial contours, with coverage designed for the delicate sub-eye area.
-
Ergonomic IPL handpiece with SapphireCool™
Treats wider areas, with continuous contact cooling for patient comfort and safety.
-
Opti-Tip
Optimizes light energy for delicate areas and supports a safe, hygienic treatment.
The procedure
Light-based, quick, 15-minute procedure.
Applied to the malar region of the face, from tragus to tragus including the nose, while the patient's eyes are fully covered by protective eyewear.
Quick procedure
About 15 minutes per procedure.
Treatment course
Visible results that last, in 4 treatments.
After treatment
Redness may occur after treatment and usually disappears within a few hours. Patients resume daily activities as advised by their doctor.
Specifications and safety information
Technical specifications
| Wavelength | 590–1200 nm, via 590 nm cut-off filter |
|---|---|
| Standard IPL wavelength range | 400–1200 nm |
| Maximal fluence | 35 J/cm² |
| Lightguides | 15 × 35 mm, 8 × 15 mm, 6.4 mm Ø |
| Cooling | Continuous contact cooling, IPL handpiece (SapphireCool™) |
| Procedure time | About 15 minutes |
| Treatment course | 4 sessions |
Indications for use
US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV.
Used in conjunction with other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. Applied to the malar region of the face, from tragus to tragus including the nose, while the eyes are fully covered by protective eyewear.
EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). This indication is intended for Fitzpatrick skin types I-V.
Contraindications
- Ocular surgery or eyelid surgery within 6 months prior to the first treatment
- Neuro-paralysis within 6 months prior to the first treatment
- Uncontrolled eye disorders affecting the ocular surface
- Pre-cancerous lesions, skin cancer or pigmented lesions in the treatment area
- Uncontrolled infections or immunosuppressive diseases
- Recent ocular infections
- History of cold sores or rashes in the perioral area (Herpes simplex 1 and 2, SLE, porphyria)
- Photosensitive medication or herbs within 3 months prior to the first IPL session
- Recent or planned radiation therapy to the head or neck
- Recent or planned chemotherapy
- History of migraines, seizures or epilepsy
Possible side effects
- Pain or discomfort
- Damage to natural skin texture
- Change of pigmentation
- Scarring
- Excessive edema
- Fragile skin
- Bruising
- Burns
- Pruritus
- Xerosis
Diagnose and treat
Pair with ANTARES diagnostics.
Lumenis' ANTARES is an advanced, automated dry eye disease diagnostic and corneal topographer.
Dry eye reportMeibographyTear breakup timeTear meniscusTopography
QualityAccurate, reliable and reproducible, with low intra-rater variability.
SpeedFast examination and fast results.
ComfortPatient comfort and physician ease of use.
Common questions about OptiLight
What is OptiLight?
OptiLight is a light-based treatment that uses precise, intense broad-spectrum light to treat dry eye disease due to meibomian gland dysfunction. It is used as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses.
Is OptiLight FDA approved?
OptiLight is the first and only IPL FDA approved for the management of dry eye disease due to meibomian gland dysfunction.
What are the key features of OptiLight?
A patented OPT™ handpiece, an ergonomic IPL handpiece with SapphireCool™ cooling, a personalized treatment experience, proven protocols and Optimal Pulse Technology.
How long does the procedure take?
About 15 minutes, with results in 4 treatments.
Is there downtime after the procedure?
Redness may occur and usually disappears within a few hours. Patients can return to daily activities as advised by their doctor.
What is OPT™ technology?
Optimal Pulse Technology delivers optimal energy with no-spike consistency, giving targeted, uniform, precise and controlled treatment designed for the delicate area below the eyes.
What wavelength does OptiLight use?
590 to 1200 nm, using a 590 nm cut-off filter.
Peer-reviewed clinical studies
- Liu R, et al. Am J Ophthalmol. 2017;183:81-90. PubMed
- Yin Y, et al. Curr Eye Res. 2018;43(3):308-313. PubMed
- Dell SJ, et al. Clin Ophthalmol. 2017;11:817-827. PubMed
- Toyos R, Briscoe D. J Clin Exp Ophthalmol. 2016;7:6.
- Kassir R, et al. J Cosmet Laser Ther. 2011;13(5):216-222. PubMed
- Papageorgiou P, et al. Br J Dermatol. 2008;159(3):628-632. PubMed
- Prieto VG, et al. Lasers Surg Med. 2002;30(2):82-85. PubMed
Bring OptiLight into your practice.
OptiLight is sold manufacturer direct through Lumenis. Explore the full product details, training and support at Lumenis.
OptiLight, OPT™, SapphireCool™ and ANTARES are trademarks of Lumenis. Dry Eye Rescue does not sell this device. Review the full Lumenis instructions for use, including all warnings, precautions, contraindications and possible side effects, before treatment. Individual results vary.
